Dose-response trial of megestrol acetate in advanced breast cancer: Cancer and leukemia group B phase III study 8741

Journal of Clinical Oncology

Volumn 17, Issue 1, 1999, Pages 64-73

  Abrams, Jeffrey ^a   Aisner, Joseph ^a   Cirrincione, Constance ^a   Berry, Donald A ^a   Muss, Hyman B ^a   Cooper, M Robert ^a   Henderson, I Craig ^a   Panasci, Lawrence ^a   Kirshner, Jeffrey ^a   Ellerton, John ^a   Norton, Larry ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; MEGESTROL ACETATE; PROGESTERONE RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; WEIGHT GAIN;

EID: 0032894762     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.1.64     Document Type: Article

References (30)

1. Haller DG, Glick JH: Progestational agents in advanced breast cancer: An overview. Semin Oncol 13:2-8, 1986 (suppl 4)
2. Schacter L, Rozencweig M, Canetta R, et al: Megestrol acetate: Clinical experience. Cancer Treat Rev 16:49-63, 1989
3. Allegra JC, Kiefer SM: Mechanisms of action of progestational agents. Semin Oncol 12:3-5, 1985 (suppl 1)
4. Lundgren S, Kvinnsland S, Varhaug JE, et al: The influence of progestins on receptor levels in breast cancer metastasis. Anticancer Res 7:119-124, 1987
5. Alexieva-Figusch J, Blankenstrin MA, Hop WCJ, et al: Treatment of metastatic breast cancer patients with different dosages of megestrol acetate: Dose relations, metabolic, and endocrine effects. Eur J Cancer Clin Oncol 20:30-40, 1984
6. Cavalli F, Goldhirsch F, Jungi F, et al: Randomized trial of low-versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer. J Clin Oncol 2:414-419, 1984
7. Pannuti F, Martoni A, Di Marco AR, et al: Prospective, randomized clinical trial of two different dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer. Eur J Cancer 15:593-601, 1979
8. Gallagher CJ, Cairnduff F, Smith IE: High dose versus low dose medroxyprogesterone acetate: A randomized trial in advanced breast cancer. Eur J Cancer Clin Oncol 23:1895-1900, 1987
9. Della Cuna GR, Calciati A, Strada MRB, et al: High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: A dose-response evaluation. Tumori 64:143-149, 1978
10. Muss HB, Case LD, Capizzi RL, et al: High- versus standard-dose megestrol acetate in women with advanced breast cancer: A phase III trial of the Piedmont Oncology Association. J Clin Oncol 8:1797-1805, 1990
11. Tchekmedyian NS, Tait N, Aisner J: High-dose megestrol acetate in the treatment of postmenopausal women with advanced breast cancer. Semin Oncol 13:20-25, 1986 (suppl 4)
12. Parnes HL, Abrams JS, Tchekmedyian NS, et al: A phase I/II study of megestrol acetate in the treatment of metastatic breast cancer. Breast Cancer Res Treat 18:171-177, 1991
13. Abrams JS, Cirrincione C, Aisner J, et al: A phase III dose-response trial of megestrol acetate (MA) in metastatic breast cancer. Proc Am Soc Clin Oncol 10:33, 1992 (abstr 50)
14. Gaver RC, Pittman KA, Reilly CM, et al: Bioequivalence evaluation of new megestrol acetate formulations in humans. Semin Oncol 12:17-19, 1985 (suppl 1)
15. Hoogstraten B, Irewin L, Ahman D, et al: Breast Cancer: Suggested Protocol Guidelines for Combination Chemotherapy Trials. Bethesda, MD. National Institutes of Health, DHEW publication (NIH) 77-1192, 1977
16. Cox DR: Regression models and life tables (with discussion). J R Soc 34:187-220, 1972
17. Kornblith AB, Hollis DR, Zuckerman E, et al: Effect of megestrol acetate upon quality of life in a dose-response trial in women with advanced breast cancer. J Clin Oncol 11:2081-2089, 1993
18. Hedley DW, Christie M, Weatherby RP, et al: Lack of correlation between plasma concentration of medroxyprogesterone acetate, hypothalamic-pituitary function, and tumour response in patients with advanced breast cancer. Cancer Chemother Pharmacol 14:112-115. 1985
19. Tseng L, Gurpide E: Effects of progestins on estradiol receptor levels in human endometrium. J Clin Endocrinol Metab 41:402-404, 1975
20. Chamness GC: Progestin action and progesterone receptors in breast cancer. Cancer Res 49:7176-7179, 1989
21. Blossey HC, Wander HE, Koebberling J, et al: Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate. Cancer 54:1208-1215, 1984
22. Buzdar A, Jonat W, Howell A, et al: Anastrozole, a potent and selective aromatase inhibitor versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase 11 trials. J Clin Oncol 14:2000-2011, 1996
23. Nagel GA, Wander HE, Blossey HC: Phase II study of aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. Cancer Res 42:3440s-3444s. 1982 (suppl 8)
24. Leinung MC, Liporace R, Miller CH: Induction of adrenal suppression by megestrol acetate in patients with AIDS. Ann Intern Med 122:843-845, 1995
25. Stoffer SS, Krakauer JC: Induction of adrenal suppression by megestrol acetate. Ann Intern Med 124:613-614, 1996 (letter)
26. Loprinzi CL, Ellison NM, Schaid DJ, et al: Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 82:1127-1132, 1990
27. Tchekmedyian NS, Hickman M, Siau J, et al: Megestrol acetate in cancer anorexia and weight loss. Cancer 69:1268-1274, 1992
28. Feliu J, Gonzalez-Baron M, Berrocal A, et al: Usefulness of megestrol acetate in cancer cachexia and anorexia. Am J Clin Oncol 15:436-440, 1992
29. Simons JP, Aaronson NK, Vansteenkiste JF, et al: Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone sensitive cancer: A placebo-controlled multicenter study. J Clin Oncol 14:1077-1084, 1996
30. Bruera E, Macmillan K, Kuehn N, et al: A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status and other symptoms in patients with advanced cancer. Cancer 66:1279-1282, 1990